Skip to main content

Search

Reset all filters
319 Result(s)
Sort by

ATM-Ranking-2021

ATM-Ranking-2021

Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
BI_X_Shanghai

BI_X_Shanghai

Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
Scam alert

Scam alert

A recruitment scam involving Boehringer Ingelheim is circulating.
European Election: Europe needs our vote

European Election: Europe needs our vote

This week, over 400 million citizens from the 27 European Union (EU) Member States will be able to elect a new European Parliament. Our vote can help to make a better and stronger Europe..
Patient Organizations

Patient Organizations

Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Combating complex diseases with data

Combating complex diseases with data

How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
vet scholars symposium

vet scholars symposium

Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
STOP Rabies: moving towards elimination

STOP Rabies: moving towards elimination

Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.